<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-36672" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cryptogenic Cirrhosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Nicolas</given-names>
          </name>
          <aff>NYU School of Medicine/NYU Langone</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Bashar</given-names>
          </name>
          <aff>SUNY Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samant</surname>
            <given-names>Hrishikesh</given-names>
          </name>
          <aff>Ochsner Multiorgan Transplant Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nicolas Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bashar Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hrishikesh Samant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-36672.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cryptogenic cirrhosis is cirrhosis of uncertain etiology that lacks definitive clinical and histological criteria for a specific disease. Although the exact cause of cryptogenic cirrhosis is unknown, correlations suggest that non-alcoholic steatohepatitis (NASH) plays a dominant role. This activity outlines the evaluation and management of cryptogenic cirrhosis and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the epidemiology of cryptogenic cirrhosis.</p></list-item><list-item><p>Assess&#x000a0;common exam findings in cryptogenic cirrhosis.</p></list-item><list-item><p>Evaluate the treatment and management options available for cryptogenic cirrhosis.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance the management of cryptogenic cirrhosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36672&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36672">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-36672.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cryptogenic cirrhosis is cirrhosis of uncertain etiology that lacks definitive&#x000a0;clinical&#x000a0;and histological criteria for a specific disease<xref ref-type="bibr" rid="article-36672.r1">[1]</xref>. Cryptogenic cirrhosis accounts for nearly 5% to 30% of cases of cirrhosis and nearly 10% of liver transplants.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r2">[2]</xref><xref ref-type="bibr" rid="article-36672.r3">[3]</xref>&#x000a0;Although the exact cause of cryptogenic cirrhosis is unknown, there are correlations that non-alcoholic steatohepatitis&#x000a0;(NASH)&#x000a0;plays a dominant role.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref></p>
      </sec>
      <sec id="article-36672.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although the exact etiology of cryptogenic cirrhosis is unknown by definition, many causes have been&#x000a0;implicated. These include NASH, occult ethanol intake, occult viral hepatitis, autoimmune hepatitis, occult biliary disease, hepatic vascular disease, celiac disease, mitochondriopathies, familial Mediterranean&#x000a0;fever, systemic lupus erythematosus, Alstrom&#x000a0;syndrome, abnormalities of apolipoprotein B with low&#x000a0;low-density-lipoprotein cholesterol, short telomere syndromes, keratin 18 mutations, and glutathione S-transferase mutations.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref></p>
      </sec>
      <sec id="article-36672.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cryptogenic&#x000a0;cirrhosis is attributed&#x000a0;as the cause of nearly 5% to 30% of cirrhosis cases and about 10% of liver transplants.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r2">[2]</xref><xref ref-type="bibr" rid="article-36672.r3">[3]</xref>&#x000a0;Nearly half of the patients with cryptogenic cirrhosis are females, and the average age is about 60 years old.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref></p>
      </sec>
      <sec id="article-36672.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the exact cause of cryptogenic cirrhosis is unknown, many potentially associated diseases with it have been described above. However, no definitive association has been made. Given the uncertain etiology, the pathophysiology of cryptogenic cirrhosis is unknown and thus requires further research to elucidate the underlying etiology before the pathophysiology can be determined.</p>
      </sec>
      <sec id="article-36672.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histological assessment is sometimes limited in those with advanced disease, but it can aid in determining the etiology of cryptogenic cirrhosis. A few studies have reported that in those being evaluated for late-stage cirrhosis and insufficient criteria to diagnose steatohepatitis, the subgroup of patients who had a&#x000a0;prior biopsy showing unequivocal nonalcoholic steatohepatitis had residual&#x000a0;histological findings.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r4">[4]</xref>&#x000a0;In these patients, the residual signs of recurrent steatohepatitis include foci of macrosteatosis, cellular ballooning, and glycogenated nuclei.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref>&#x000a0;Predominant type and distribution of inflammation, apoptotic&#x000a0;bodies, bile ductular proliferation, and&#x000a0;Mallory-Denk bodies may also be present in histology.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref></p>
      </sec>
      <sec id="article-36672.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Approximately 10% of cases of cryptogenic cirrhosis are discovered incidentally during evaluation of other issues, such as possible&#x000a0;gallbladder disease, and&#x000a0;nearly 45% of patients only had complaints of vague symptoms such as fatigue&#x000a0;or previously unexplained lab abnormalities.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref>&#x000a0;However, nearly 45% of patients had complications of portal hypertension, including new-onset ascites, encephalopathy, or variceal bleeding<xref ref-type="bibr" rid="article-36672.r1">[1]</xref>.&#x000a0;Occasionally, patients with cryptogenic cirrhosis present with hepatocellular cancer.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r5">[5]</xref><xref ref-type="bibr" rid="article-36672.r6">[6]</xref><xref ref-type="bibr" rid="article-36672.r7">[7]</xref>&#x000a0;Moreover,&#x000a0;due to the close association between cryptogenic cirrhosis and nonalcoholic steatohepatitis, and as a result&#x000a0;of metabolic syndrome, patients may present with both cardiovascular disease and cirrhosis.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r8">[8]</xref><xref ref-type="bibr" rid="article-36672.r9">[9]</xref></p>
        <p>Important history to obtain would entail a&#x000a0;prior diagnosis of fatty liver disease, obesity, diabetes,&#x000a0;hyperlipidemia, exposure to blood or needles, family history of liver disease, personal or family history of autoimmune diseases, alcohol history, medication history such as methotrexate, and occupational history.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref>&#x000a0;Patients with cryptogenic cirrhosis may present similarly to those with cirrhosis from other known&#x000a0;etiologies. They may have signs and symptoms that include jaundice, altered mental status, palmar erythema, spider angiomata,&#x000a0;abdominal distention, weight loss, edema,&#x000a0;varices, asterixis, and other cause-specific&#x000a0;findings.</p>
      </sec>
      <sec id="article-36672.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory testing should include viral hepatitis studies, autoimmune profiles, quantitative immunoglobulin levels, iron studies, alpha-1-antitrypsin phenotype and level, Wilson disease markers, and celiac disease markers.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref><xref ref-type="bibr" rid="article-36672.r10">[10]</xref>&#x000a0;Aminotransferase levels, such as AST and ALT, are typically only mildly elevated or normal in those with cryptogenic cirrhosis. A definitive&#x000a0;diagnosis also requires a biopsy. Histological markers include a predominant type and distribution of inflammation, cellular ballooning, Mallory-Denk&#x000a0;bodies, glycogenated nuclei, foci of macrosteatosis, bile ductular proliferation, and apoptotic bodies.<xref ref-type="bibr" rid="article-36672.r1">[1]</xref></p>
      </sec>
      <sec id="article-36672.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The definitive treatment for cryptogenic cirrhosis is transplantation. However, given the close association between cryptogenic cirrhosis and NASH, medical management until transplant may be beneficial. Lifestyle modifications such as weight loss, physical exercise, and a healthy&#x000a0;diet are&#x000a0;recommended. Although&#x000a0;NASH is&#x000a0;related to the development of cryptogenic cirrhosis, there are other potential associations&#x000a0;as well. Specific treatment for those etiologies is also recommended.</p>
      </sec>
      <sec id="article-36672.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Diseases that can be mistaken for&#x000a0;cryptogenic cirrhosis are other etiologies of cirrhosis. The differential for the etiology of cirrhosis is broad. It includes but is not limited to alcoholic liver disease, non-alcoholic&#x000a0;fatty liver disease, hepatitis B and C, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, IgG4 cholangiopathy, recurrent bacterial cholangitis, bile duct stenosis, Budd-Chiari syndrome, right heart failure, Osler disease, hemochromatosis, Wilson&#x000a0;disease, and alpha-1-antitrypsin deficiency.<xref ref-type="bibr" rid="article-36672.r11">[11]</xref>&#x000a0;A thorough history and physical exam with laboratory and imaging tests can detect a diagnosis of cirrhosis. Once cirrhosis is&#x000a0;diagnosed, risk factors and further testing, including biopsy, can help determine the specific etiology of cirrhosis.</p>
      </sec>
      <sec id="article-36672.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Those with a diagnosis of cryptogenic cirrhosis are at high risk of developing hepatocellular carcinoma. Given this risk, it is recommended that patients be screened every 6 months for hepatocellular carcinoma using ultrasound imaging of the liver. Other screening modalities exist, such as computed tomography imaging, magnetic resonance imaging, and alpha-fetoprotein lab testing. However,&#x000a0;ultrasound imaging is the primary modality for screening. Often, alpha-fetoprotein is an additional test and an ultrasound but should not be used alone.</p>
      </sec>
      <sec id="article-36672.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In the study by Rinaldi et al, they found that over a median follow-up period of 42 months, the percentage of deaths in those with cryptogenic cirrhosis was 39.2% compared to HCV-related cirrhosis, which was 30%.<xref ref-type="bibr" rid="article-36672.r12">[12]</xref>&#x000a0;Moreover,&#x000a0;the median survival was 60 months for those with cryptogenic cirrhosis.<xref ref-type="bibr" rid="article-36672.r12">[12]</xref>&#x000a0;The Model For End-Stage Liver Disease (MELD) score is a calculation aimed at determining the severity of end-stage liver disease and the need for transplantation. The components of the MELD score include creatinine, bilirubin, INR, and sodium.</p>
      </sec>
      <sec id="article-36672.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of cryptogenic cirrhosis include the same complications one would find with other causes of cirrhosis. These complications include&#x000a0;hepatocellular carcinoma, hepatorenal syndrome, hepatopulmonary syndrome, variceal bleeding, ascites, spontaneous bacterial peritonitis, and hepatic encephalopathy. Additional potential complications for cryptogenic cirrhosis include heart disease, renal disease, and other potential complications of diabetes, such as retinopathy. Additional complications depend on the underlying etiology of cryptogenic cirrhosis.</p>
      </sec>
      <sec id="article-36672.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>The care of a patient with cryptogenic cirrhosis includes a primary care physician and a gastroenterologist, a hepatologist, a transplant team, a nutritionist, and a social worker. A primary care physician has an important role in identifying those at risk of cirrhosis or liver disease and ordering the pertinent&#x000a0;tests and imaging necessary for diagnosis before a consultant gets involved. A gastroenterologist can help progress the management of the patient's care and diagnose some of the complications associated with cryptogenic cirrhosis, such as esophageal varices, via endoscopy. A hepatologist can provide further expertise in additional treatment and management that can be beneficial. Once the patient is deemed a candidate for transplant, further planning, including lab testing, imaging, and history taking, can be done by transplant hepatologists and surgeons. Given the close association between cryptogenic cirrhosis and NASH, nutritionists&#x000a0;play a pivotal role in lifestyle and diet modification. Lastly, social workers are key team members as they can coordinate care between all the physicians and ensure the patient has&#x000a0;travel accommodations not to miss appointments.</p>
      </sec>
      <sec id="article-36672.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Cryptogenic cirrhosis can be a life-altering disease. Those patients at risk or who have a family history of liver disease, obesity, diabetes, hypertension, or hyperlipidemia are encouraged to see their primary care physician routinely. If one is at high risk of cryptogenic cirrhosis, medication compliance, lifestyle and diet modifications, and surveillance are important. It is also imperative&#x000a0;to follow up with a gastroenterologist and hepatologist for expert advice and potential placement for transplant.</p>
      </sec>
      <sec id="article-36672.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Although the exact cause of cryptogenic cirrhosis is unknown, nonalcoholic steatohepatitis is thought to have a large role. Metabolic problems such as diabetes, hyperlipidemia, and obesity have all been associated with the development of this disease. Lifestyle and diet modification must be encouraged in these patients. Also, once they develop cryptogenic cirrhosis, screening&#x000a0;for hepatocellular carcinoma every 6 months is advised.</p>
      </sec>
      <sec id="article-36672.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of cryptogenic cirrhosis, like all causes, requires a&#x000a0;team-based approach to have high-quality care. The coordination between primary care physicians, gastroenterologists, hepatologists, transplant hepatologists and surgeons, nutritionists, and social workers is vital to this care. An interprofessional, team-based approach to patient care can help prevent many complications associated with cryptogenic cirrhosis. It can potentially slow its progression if the specific etiology is targeted&#x02014;for example, management of metabolic derangements in those with underlying NASH through lifestyle and diet modifications. Common&#x000a0;complications of cryptogenic cirrhosis can include the need for a transjugular intrahepatic portosystemic shunt, varices, ascites, spontaneous bacterial peritonitis, and hepatic encephalopathy. The management of these complications is much better when the patient's care is coordinated&#x000a0;between healthcare providers.<xref ref-type="bibr" rid="article-36672.r13">[13]</xref></p>
      </sec>
      <sec id="article-36672.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36672&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36672">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/cryptogenic-cirrhosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=36672">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/36672/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=36672">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-36672.s19">
        <title>References</title>
        <ref id="article-36672.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cryptogenic cirrhosis: what are we missing?</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-8</page-range>
            <pub-id pub-id-type="pmid">20425483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.</article-title>
            <source>JAMA</source>
            <year>2003</year>
            <month>Jun</month>
            <day>11</day>
            <volume>289</volume>
            <issue>22</issue>
            <fpage>3000</fpage>
            <page-range>3000-4</page-range>
            <pub-id pub-id-type="pmid">12799409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.</article-title>
            <source>J Hepatol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>578</fpage>
            <page-range>578-84</page-range>
            <pub-id pub-id-type="pmid">15030972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Al-Osaimi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Argo</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Northup</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>NASH and cryptogenic cirrhosis: a histological analysis.</article-title>
            <source>Ann Hepatol</source>
            <year>2009</year>
            <season>Oct-Dec</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>346</fpage>
            <page-range>346-52</page-range>
            <pub-id pub-id-type="pmid">20009134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cotrim</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Paran&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Braga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lyra</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?</article-title>
            <source>Am J Gastroenterol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>10</issue>
            <fpage>3018</fpage>
            <page-range>3018-9</page-range>
            <pub-id pub-id-type="pmid">11051414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratziu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bonyhay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Martino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cavallaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sayegh-Tainturier</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Giral</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Opolon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poynard</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.</article-title>
            <source>Hepatology</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1485</fpage>
            <page-range>1485-93</page-range>
            <pub-id pub-id-type="pmid">12029634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Al-Osaimi</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Obesity and hepatocellular carcinoma.</article-title>
            <source>Gastroenterology</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>127</volume>
            <issue>5 Suppl 1</issue>
            <fpage>S97</fpage>
            <page-range>S97-103</page-range>
            <pub-id pub-id-type="pmid">15508109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Banas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sargeant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Stravitz</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Shiffman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Heuman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coterrell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Contos</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>682</fpage>
            <page-range>682-9</page-range>
            <pub-id pub-id-type="pmid">16502396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gastaldelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kozakova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f8;jlund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flyvbjerg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Favuzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitrakou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balkau</surname>
                <given-names>B</given-names>
              </name>
              <collab>RISC Investigators</collab>
            </person-group>
            <article-title>Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population.</article-title>
            <source>Hepatology</source>
            <year>2009</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>1537</fpage>
            <page-range>1537-44</page-range>
            <pub-id pub-id-type="pmid">19291789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubio-Tapia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The liver in celiac disease.</article-title>
            <source>Hepatology</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>1650</fpage>
            <page-range>1650-8</page-range>
            <pub-id pub-id-type="pmid">17969053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiegand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>85</fpage>
            <page-range>85-91</page-range>
            <pub-id pub-id-type="pmid">23451000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinaldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nascimbeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Masetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guerrera</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amelia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fascione</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ballestri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Romagnoli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zampino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nevola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baldelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iuliano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lonardo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adinolfi</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>28</day>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>1458</fpage>
            <page-range>1458-1468</page-range>
            <pub-id pub-id-type="pmid">28293093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36672.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mellinger</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary management of patients with cirrhosis: a need for care coordination.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>217</fpage>
            <page-range>217-23</page-range>
            <pub-id pub-id-type="pmid">23142204</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
